This is the shared pathway across all three compounds
Meal Timing and Managing Gastrointestinal Side Effects Appetite suppression and nausea are common early on tirzepatide
Secondary outcomes included absolute change in body weight and weight circumference from 36 to 88 weeks, the percentage of adults achieving at least a 5%, 10%, 15%, 20% or 25% weight loss from baseline to 88 weeks and the percentage of adults that maintained at least 80% of the body weight they lost during the open-label period
Either approach is reasonable and should be guided by your individual experience and practitioner recommendations
FDA-approved drugs undergo rigorous testing and must be proven to work as intended in clinical trials
Warning signs that your dose might be too high include severe or persistent nausea, frequent vomiting, significant digestive issues, excessive fatigue, or dehydration